Servier S.A.S. Deal History & Licensing Activity
Servier S.A.S. is a mid-size pharma. Over the past three years, Servier S.A.S. has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (6 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
3
Active Trials
50
Top Modality
Small Molecules
Focus Area
Solid Tumors
Servier S.A.S. Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Servier S.A.S. in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Muscular dystrophy program | Servier | Small Molecules | Unknown | license | Jun 15, 2026 |
| EDG-5506 | Servier | Small Molecules | Phase 2 | acquisition | Jun 3, 2026 |
| Tovorafenib (DAY101) | Servier | Small Molecules | Unknown | acquisition |
Servier S.A.S. Pipeline Focus
Therapeutic areas and modalities where Servier S.A.S. is most active based on deal history and clinical trial data.
Therapeutic Areas
Servier S.A.S. Strategic Signals
Key indicators of Servier S.A.S.'s licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Servier S.A.S. Clinical Pipeline
Servier S.A.S. has 50 active clinical trials across 5 development phases.
9
Unknown
4
Not Applicable
19
Phase 1
12
Phase 2
6
Phase 3
See How Your Asset Matches Servier S.A.S.'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Servier S.A.S. Licensing & Deal Activity
Servier S.A.S. is a mid-size pharma company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Servier S.A.S. ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Servier S.A.S. include Solid Tumors (16 deals and trials), Hematological Malignancies (13 deals and trials), CNS Disorders (7 deals and trials), and Rare Disease (4 deals and trials). In terms of modality, Servier S.A.S. has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Servier S.A.S. and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Servier S.A.S.'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.